Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3396-3403

  Kurtzberg, J ^a   Ernst, T J ^a   Keating, M J ^a   Gandhi, V ^a   Hodge, J P ^a   Kisor, D F ^a   Lager, J J ^a   Stephens, C ^a   Levin, J ^a   Krenitsky, T ^a   Elion, G ^a   Mitchell, B S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BICARBONATE; NELARABINE; ARABINONUCLEOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; BRAIN DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG MECHANISM; FATIGUE; FEMALE; FEVER; GAIT DISORDER; HEADACHE; HUMAN; HYPESTHESIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; MUSCLE WEAKNESS; NAUSEA; NEUROMUSCULAR DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARALYSIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REFLEX; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; VOMITING; ADOLESCENT; BLOOD DISEASE; CANCER INVASION; CANCER STAGING; CHILD; DRUG ADMINISTRATION; DRUG RESISTANCE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ARABINONUCLEOSIDES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECURRENCE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 20644435369     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.199     Document Type: Article

References (23)

1. Giblett ER, Ammann AJ, Wara DW, et al: Nucleoside phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1:1010-1013, 1975
2. Carson DA, Kaye J, Seegmiller JE: Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A 74:5677-5681, 1977
3. Carson DA, Kaye J, Matsumoto S, et al: Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A 76:2430-2433, 1979
4. Mitchell BS, Mejias E, Daddona PE, et al: Purinogenic immunodeficiency diseases: Selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A 75:5011-5014, 1978
5. Reist EJ, Goodman L: Synthtesis of 9-beta-D-arabinofuranosylguanine. Biochemistry 3:15, 1964
6. Cohen A, Lee JW, Gelfand EW: Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 61:660-666, 1983
7. Scharenberg JG, Spappen LJ, Rijkers GT, et al: Mechanisms of deoxyguanosine toxicity for human T and B lymphocytes. Adv Exp Med Biol 195B:191-199, 1986
8. Shewach DS, Daddona PE, Ashcraft E, et al: Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res 45:1008-1014, 1985
9. Verhoef V, Fridland A: Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res 45:3646-3650, 1985
10. Hebert ME, Greenberg M, Chaffee S, et al: Pharmacologic purging of malignant human T cells from human bone marrow using 9-beta-D- arabinofuranosylguanine. Transplantation 52:634-640, 1991
11. Kurtzberg J: Guanine arabinoside as a bone marrow purging agent. Ann NY Acad Sci 685:225-236, 1993
12. Gravatt LC, Chaffee S, Hebert ME, et al: Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T-cells from murine bone marrow: Application to an in vivo T-leukemia model. Leukemia 7:1261-1267, 1993
13. Krenitsky TA, Koszalka GW, Tuttle JV, et al: An enzymatic synthesis of purine-D-arabinonucleosides. Carbohydrate Res 97:139-146, 1981
14. Lambe CU, Averett DR, Paff MT, et al: 2-amino-6-methoxypurine arabinoside: An agent for T-cell malignancies. Cancer Res 55:3352-3356, 1995
15. Gandhi V, Plunkett W, Rodriguez CO, et al: Compound GW506U78 in refractory hematologic malignancies - relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16:3607-3615, 1998
16. Kisor DF, Plunkett W, Kurtzberg J, et al: The pharmacokinetics of 506U78 and 9-Beta-D-Arabinofuranosyl Guanine in pediatric and adult patients during a phase I study of 506U78 for the treatment of refractory hematological malignancies. J Clin Oncol 18:995-1003, 2000
17. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
18. Cheson BD, Vena DA, Foss FM, et al: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216-2228, 1994
19. Gandhi V, Plunkett W, Weller S, et al: Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J Clin Oncol 19:2142-2152, 2001
20. Rodriguez CO Jr, Legha JK, Estey E, et al: Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemic cells. Clin Cancer Res 3:2107-2113, 1997
21. Rodriguez CO Jr, Stellrecht CM, Gandhi V: Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 102:1842-1848, 2003
22. DeAngelo DJ, Yu D, Dodge RK, et al: A phase II study of 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB Study 19801. Blood 100:198a, 2002 (abstr 743)
23. Berg SL, Blaney SM, Bernstein M, et al: Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG Intergroup Phase 2 study. Blood 102:226a, 2003 (abstr 792)